490 related articles for article (PubMed ID: 30696949)
21. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Richardson PG; Kumar SK; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Gimsing P; Garderet L; Touzeau C; Buadi FK; Laubach JP; Cavo M; Darif M; Labotka R; Berg D; Moreau P
J Clin Oncol; 2021 Aug; 39(22):2430-2442. PubMed ID: 34111952
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy and Safety of Ixazomib-Lenalidomide-Dexamethasone Therapy for Relapsed and Refractory Multiple Myeloma].
Takakuwa T; Araki T; Miura A; Fujitani Y; Takeoka Y; Ohta K; Yamamura R
Gan To Kagaku Ryoho; 2019 Jun; 46(6):1043-1047. PubMed ID: 31273172
[TBL] [Abstract][Full Text] [Related]
23. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
Dimopoulos MA; Schjesvold F; Doronin V; Vinogradova O; Quach H; Leleu X; Montes YG; Ramasamy K; Pompa A; Levin MD; Lee C; Mellqvist UH; Fenk R; Demarquette H; Sati H; Vorog A; Labotka R; Du J; Darif M; Kumar S
Blood Cancer J; 2022 Jan; 12(1):9. PubMed ID: 35075109
[TBL] [Abstract][Full Text] [Related]
24. Ixazomib in the management of relapsed multiple myeloma.
Touzeau C; Moreau P
Future Oncol; 2018 Aug; 14(20):2013-2020. PubMed ID: 29469592
[TBL] [Abstract][Full Text] [Related]
25. [Clinical Efficacy and Safety of Ixazomib-Containing Regimens in the Treatment of Patients with Multiple Myeloma].
Chen R; Xue LG; Zhou H; Jia T; Cai ZM; Zhu YX; Miao L; Wei JF; Zhao LD; Mao JP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):483-492. PubMed ID: 38660856
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
Gupta N; Goh YT; Min CK; Lee JH; Kim K; Wong RS; Chim CS; Hanley MJ; Yang H; Venkatakrishnan K; Hui AM; Esseltine DL; Chng WJ
J Hematol Oncol; 2015 Sep; 8():103. PubMed ID: 26337806
[TBL] [Abstract][Full Text] [Related]
27. Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
Suzuki K; Handa H; Chou T; Ishizawa K; Takubo T; Kase Y
Int J Hematol; 2017 Apr; 105(4):445-452. PubMed ID: 28000099
[TBL] [Abstract][Full Text] [Related]
28. Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma.
Kumar SK; Grzasko N; Delimpasi S; Jedrzejczak WW; Grosicki S; Kyrtsonis MC; Spencer A; Gupta N; Teng Z; Byrne C; Labotka R; Dimopoulos MA
Br J Haematol; 2019 Feb; 184(4):536-546. PubMed ID: 30460684
[TBL] [Abstract][Full Text] [Related]
29. Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma.
Kumar SK; Buadi FK; LaPlant B; Halvorson A; Leung N; Kapoor P; Dingli D; Gertz MA; Go RS; Bergsagel PL; Lin Y; Dispenzieri A; Hwa YL; Fonder A; Hobbs M; Fonseca R; Hayman SR; Stewart AK; Lust JA; Mikhael J; Gonsalves W; Reeder C; Skacel T; Rajkumar SV; Lacy MQ
Blood Cancer J; 2018 Jul; 8(8):70. PubMed ID: 30061664
[TBL] [Abstract][Full Text] [Related]
30. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA; Gay F; Schjesvold F; Beksac M; Hajek R; Weisel KC; Goldschmidt H; Maisnar V; Moreau P; Min CK; Pluta A; Chng WJ; Kaiser M; Zweegman S; Mateos MV; Spencer A; Iida S; Morgan G; Suryanarayan K; Teng Z; Skacel T; Palumbo A; Dash AB; Gupta N; Labotka R; Rajkumar SV;
Lancet; 2019 Jan; 393(10168):253-264. PubMed ID: 30545780
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma.
Patel KK; Shah JJ; Feng L; Lee HC; Manasanch EM; Olsem J; Morphey A; Huo XJ; Thomas SK; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ
Clin Cancer Res; 2022 Apr; 28(7):1277-1284. PubMed ID: 34992070
[TBL] [Abstract][Full Text] [Related]
32. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib.
Kumar SK; LaPlant BR; Reeder CB; Roy V; Halvorson AE; Buadi F; Gertz MA; Bergsagel PL; Dispenzieri A; Thompson MA; Crawley J; Kapoor P; Mikhael J; Stewart K; Hayman SR; Hwa YL; Gonsalves W; Witzig TE; Ailawadhi S; Dingli D; Go RS; Lin Y; Rivera CE; Rajkumar SV; Lacy MQ
Blood; 2016 Nov; 128(20):2415-2422. PubMed ID: 27702799
[TBL] [Abstract][Full Text] [Related]
33. Ixazomib for the treatment of multiple myeloma.
Richardson PG; Zweegman S; O'Donnell EK; Laubach JP; Raje N; Voorhees P; Ferrari RH; Skacel T; Kumar SK; Lonial S
Expert Opin Pharmacother; 2018 Dec; 19(17):1949-1968. PubMed ID: 30422008
[TBL] [Abstract][Full Text] [Related]
34. Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma.
Sokol J; Guman T; Chudej J; Hlebaskova M; Stecova N; Valekova L; Kucerikova M; Stasko J
Ann Hematol; 2022 Jan; 101(1):81-89. PubMed ID: 34550463
[TBL] [Abstract][Full Text] [Related]
35. Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: A real-world study.
Shen M; Zhang J; Tang R; Wang Y; Zhan X; Fan S; Huang Z; Zhong Y; Li X
Cancer Med; 2022 Jun; 11(11):2173-2183. PubMed ID: 34655168
[TBL] [Abstract][Full Text] [Related]
36. Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial.
Dimopoulos MA; Špička I; Quach H; Oriol A; Hájek R; Garg M; Beksac M; Bringhen S; Katodritou E; Chng WJ; Leleu X; Iida S; Mateos MV; Morgan G; Vorog A; Labotka R; Wang B; Palumbo A; Lonial S;
J Clin Oncol; 2020 Dec; 38(34):4030-4041. PubMed ID: 33021870
[TBL] [Abstract][Full Text] [Related]
37. Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study.
Stege CAM; Nasserinejad K; van der Spek E; Bilgin YM; Kentos A; Sohne M; van Kampen RJW; Ludwig I; Thielen N; Durdu-Rayman N; de Graauw NCHP; van de Donk NWCJ; de Waal EGM; Vekemans MC; Timmers GJ; van der Klift M; Soechit S; Geerts PAF; Silbermann MH; Oosterveld M; Nijhof IS; Sonneveld P; Klein SK; Levin MD; Zweegman S
J Clin Oncol; 2021 Sep; 39(25):2758-2767. PubMed ID: 33945289
[TBL] [Abstract][Full Text] [Related]
38. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
Voorhees PM; Suman VJ; Tuchman SA; Laubach JP; Hassoun H; Efebera YA; Mulkey F; Bova-Solem M; Santo K; Carlisle D; McCarthy PL; Richardson PG
Am J Hematol; 2021 Dec; 96(12):1595-1603. PubMed ID: 34559902
[TBL] [Abstract][Full Text] [Related]
39. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone.
Nadeem O; Aranha MP; Redd R; Timonian M; Magidson S; Lightbody ED; Alberge JB; Bertamini L; Dutta AK; El-Khoury H; Bustoros M; Laubach JP; Bianchi G; O'Donnell E; Wu T; Tsuji J; Anderson K; Getz G; Trippa L; Richardson PG; Sklavenitis-Pistofidis R; Ghobrial IM
medRxiv; 2024 Apr; ():. PubMed ID: 38699307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
